$VTVT
vTv Therapeutics Inc.

2019 Q1 Form 10-Q Financial Statement

#000156459019014845 Filed on May 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $921.0K $2.064M
YoY Change -55.38% 6780.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.390M $2.260M
YoY Change 5.75% -19.86%
% of Gross Profit
Research & Development $2.820M $8.940M
YoY Change -68.46% -18.43%
% of Gross Profit
Depreciation & Amortization $8.000K $42.00K
YoY Change -80.95% -19.23%
% of Gross Profit
Operating Expenses $5.210M $11.20M
YoY Change -53.48% -18.75%
Operating Profit -$4.287M -$9.134M
YoY Change -53.07% -33.59%
Interest Expense $626.0K -$840.0K
YoY Change -174.52% -250.27%
% of Operating Profit
Other Income/Expense, Net $920.0K $10.00K
YoY Change 9100.0%
Pretax Income -$3.982M -$9.960M
YoY Change -60.02% -30.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.155M -$2.952M
YoY Change -27.0% -30.05%
Net Earnings / Revenue -233.98% -143.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$94.49K -$304.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.000M $6.500M
YoY Change -23.08% -85.62%
Cash & Equivalents $7.459M $9.035M
Short-Term Investments
Other Short-Term Assets $400.0K $2.800M
YoY Change -85.71% 250.0%
Inventory
Prepaid Expenses
Receivables $200.0K
Other Receivables $0.00
Total Short-Term Assets $5.400M $9.500M
YoY Change -43.16% -79.3%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $200.0K
YoY Change 50.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M $2.500M
YoY Change 0.0%
Other Assets $2.500M $2.500M
YoY Change 0.0% 25.0%
Total Long-Term Assets $5.300M $5.200M
YoY Change 1.92% 116.67%
TOTAL ASSETS
Total Short-Term Assets $5.400M $9.500M
Total Long-Term Assets $5.300M $5.200M
Total Assets $10.70M $14.70M
YoY Change -27.21% -69.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.200M $11.30M
YoY Change -45.13% 1.8%
Accrued Expenses $300.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.200M $6.800M
YoY Change 35.29%
Total Short-Term Liabilities $16.50M $26.80M
YoY Change -38.43% 141.44%
LONG-TERM LIABILITIES
Long-Term Debt $4.000M $13.10M
YoY Change -69.47% -30.32%
Other Long-Term Liabilities $2.800M $3.200M
YoY Change -12.5% 966.67%
Total Long-Term Liabilities $6.800M $16.30M
YoY Change -58.28% -14.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.50M $26.80M
Total Long-Term Liabilities $6.800M $16.30M
Total Liabilities $68.50M $163.5M
YoY Change -58.1% -4.83%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$57.74M -$148.8M
YoY Change
Total Liabilities & Shareholders Equity $10.70M $14.70M
YoY Change -27.21% -69.57%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$2.155M -$2.952M
YoY Change -27.0% -30.05%
Depreciation, Depletion And Amortization $8.000K $42.00K
YoY Change -80.95% -19.23%
Cash From Operating Activities -$5.450M -$5.397M
YoY Change 0.98% -60.95%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K
YoY Change -100.0%
Cash From Investing Activities $0.00 $12.00K
YoY Change -100.0% -130.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.443M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.726M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.450M -5.397M
Cash From Investing Activities 0.000 12.00K
Cash From Financing Activities 8.726M 0.000
Net Change In Cash 3.276M -5.385M
YoY Change -160.84% -15.33%
FREE CASH FLOW
Cash From Operating Activities -$5.450M -$5.397M
Capital Expenditures $0.00
Free Cash Flow -$5.397M
YoY Change -61.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2018Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1124000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
259000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9960000
CY2018Q4 us-gaap Liabilities
Liabilities
28930000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1752000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9383000
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
6330000
CY2018Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
151000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1067000
CY2018Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
2436000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
62482000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
150595000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233883000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-82853000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8559000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-3982000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-9960000
CY2019Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1827000
CY2018Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7008000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2155000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2952000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5883000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2952000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
281000
CY2019Q1 vtvt Stock Issued During Period Value Conversion Of Convertible Securities Under Direct Offering
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUnderDirectOffering
5443000
CY2019Q1 vtvt Stock Issued During Period Value Conversion Of Convertible Securities Related Party
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedParty
6000000
CY2019Q1 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
15549000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-151047000
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
213000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
963000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
151000
CY2018Q1 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
3884000
CY2019Q1 us-gaap Depreciation
Depreciation
8000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
281000
CY2019Q1 vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
-921000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8726000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14420000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7459000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9035000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1445000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-913000
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-35000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5450000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5397000
CY2018Q1 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
12000
CY2019Q1 vtvt Proceeds From Issuance Of Common Stock To Related Party
ProceedsFromIssuanceOfCommonStockToRelatedParty
6000000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5443000
CY2019Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2717000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3276000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5385000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4183000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of derivative liabilities, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p>
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two customers represented 100% of the revenue earned during the three months ended March&#160;31, 2019.&nbsp;&nbsp;Two customers represented 100% of the revenue earned during the three months ended March&#160;31, 2018. </p>
CY2019Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
11500000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1906000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2819000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7115
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0269
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1767503
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
948500
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50143
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2665860
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1415223
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2603440
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.57
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.30
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.61
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.40
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.40
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.47
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
281000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
963000
CY2019Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12397000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14897000
CY2018Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
216000
CY2019Q1 vtvt Accreted Final Payment
AccretedFinalPayment
-784000
CY2018Q4 vtvt Accreted Final Payment
AccretedFinalPayment
-600000
CY2019Q1 us-gaap Notes Payable
NotesPayable
13181000
CY2018Q4 us-gaap Notes Payable
NotesPayable
15713000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2018Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
300000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
400000
CY2019Q1 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
45100000
CY2018Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
62500000
CY2019Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
7429000
CY2018Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
21000
CY2019Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-13312000
CY2018Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-2973000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q1 vtvt Deemed Distribution To Related Party
DeemedDistributionToRelatedParty
3728000
CY2019Q1 vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-5883000
CY2018Q1 vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2952000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33833033
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27780245
CY2019Q1 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2018-12-11
CY2019Q1 us-gaap Severance Costs1
SeveranceCosts1
300000

Files In Submission

Name View Source Status
0001564590-19-014845-index-headers.html Edgar Link pending
0001564590-19-014845-index.html Edgar Link pending
0001564590-19-014845.txt Edgar Link pending
0001564590-19-014845-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gkn1g2pi5isr000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtvt-10q_20190331.htm Edgar Link pending
vtvt-20190331.xml Edgar Link completed
vtvt-20190331.xsd Edgar Link pending
vtvt-20190331_cal.xml Edgar Link unprocessable
vtvt-20190331_def.xml Edgar Link unprocessable
vtvt-20190331_lab.xml Edgar Link unprocessable
vtvt-20190331_pre.xml Edgar Link unprocessable
vtvt-ex311_11.htm Edgar Link pending
vtvt-ex312_10.htm Edgar Link pending
vtvt-ex321_7.htm Edgar Link pending
vtvt-ex322_8.htm Edgar Link pending